SCHEDULE 13G 0001465302 XXXXXXXX LIVE Common Stock, par value $0.005 per share 03/31/2025 0000748592 Ernexa Therapeutics Inc. 114082209 1035 Cambridge Street Suite 18A Cambridge MA 02141 Rule 13d-1(c) Shameek Konar X1 0.00 3435304.00 0.00 3435304.00 3435304.00 N 5.5 IN Rows 6 and 8 consist of (i) 3,343,192 shares of the Common Stock of Ernexa Therapeutics Inc. (formerly Eterna Therapeutics Inc., the "Issuer") owned by Regolith Capital Investments LP ("Regolith") and (ii) 92,112 shares of common stock owned by Mr. Konar. Mr. Konar and Victoria Konar are the general partners of Regolith and Mr. Konar disclaims beneficial ownership of the securities held by Regolith except to the extent of his pecuniary interest therein. Row 11 is calculated based on 62,363,763 shares of the Common Stock of the Issuer outstanding as of May 7, 2025 as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 filed with the Securities and Exchange Commission (the "SEC") on May 7, 2025. The number of shares beneficially owned in Rows 6, 8 and 9 and the number of shares outstanding for purposes of Row 11 do not include shares that will be issued to Regolith pursuant to that certain Securities Purchase Agreement dated as of March 31, 2025 between the Issuer and the purchasers identified on the signature pages thereto, including Regolith (the "SPA"), following the receipt of stockholder approval at the Issuer's annual meeting of stockholders to be held on June 2, 2025. Victoria Konar X1 0.00 3435304.00 0.00 3435304.00 3435304.00 N 5.5 IN Rows 6 and 8 consist of (i) 3,343,192 shares of the Common Stock of the Issuer owned by Regolith and (ii) 92,112 shares of common stock owned by Ms. Konar's spouse, Shameek Konar. Ms. Konar and Shameek Konar are the general partners of Regolith and Ms. Konar disclaims beneficial ownership of the securities held by Regolith except to the extent of her pecuniary interest therein. Row 11 is calculated based on 62,363,763 shares of the Common Stock of the Issuer outstanding as of May 7, 2025 as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 filed with the SEC on May 7, 2025. The number of shares beneficially owned in Rows 6, 8 and 9 and the number of shares outstanding for purposes of Row 11 do not include shares that will be issued to Regolith pursuant to the SPA, following the receipt of stockholder approval at the Issuer's annual meeting of stockholders to be held on June 2, 2025. Regolith Capital Investments LP TX 0.00 3343192.00 0.00 3343192.00 3343192.00 N 5.4 PN Regolith is a Texas limited liability partnership. Shameek Konar and Victoria Konar are the general partners of Regolith. Row 11 is calculated based on 62,363,763 shares of the Common Stock of the Issuer outstanding as of May 7, 2025 as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 filed with the SEC on May 7, 2025. The number of shares beneficially owned in Rows 6, 8 and 9 and the number of shares outstanding for purposes of Row 11 do not include shares that will be issued to Regolith pursuant to the SPA, following the receipt of stockholder approval at the Issuer's annual meeting of stockholders to be held on June 2, 2025. Ernexa Therapeutics Inc. 1035 Cambridge Street Suite 18A Cambridge, MA, 02141 This statement is filed by the following entity and individuals (collectively referred to as the "Reporting Persons") Shameek Konar Victoria Konar Regolith Capital Investments LP Shameek Konar and Victora Konar are the general partners of Regolith Capital Investments LP, and as a result, may be deemed to share voting and dispositive power with respect to the securities held by Regolith Capital Investments LP. Regolith Capital Investments LP, Mr. Konar and Ms. Konar have entered into a Joint Filing Agreement, a copy of which is filed as Exhibit 99.1 to this Schedule 13G and is hereby incorporated by reference, pursuant to which they have agreed to file this Amendment jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended. The address for each of the Reporting Persons is 10608 Stoppard View Way, Knoxville, TN 37922 See Row 4 of each Reporting Person's cover page to this Schedule 13G. Y See Row 9 of each Reporting Person's cover page to this Schedule 13G. See Row 11 of each Reporting Person's cover page to this Schedule 13G. See Row 5 of each Reporting Person's cover page to this Schedule 13G. See Row 6 of each Reporting Person's cover page to this Schedule 13G. See Row 7 of each Reporting Person's cover page to this Schedule 13G. See Row 8 of each Reporting Person's cover page to this Schedule 13G. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Shameek Konar /s/ Shameek Konar 05/15/2025 Victoria Konar /s/ Victoria Konar 05/15/2025 Regolith Capital Investments LP /s/ Shameek Konar 05/15/2025